Open AccessA Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2
Author(s) -
Ratish Gambhira,
Balasubramanyam Karanam,
Subhashini Jagu,
Jeffrey N. Roberts,
Christopher B. Buck,
Ioannis Bossis,
Hannah H. Alphs,
Timothy D. Culp,
Neil D. Christensen,
Richard B.S. Roden
Publication year - 2007
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.00936-07
Subject(s) - neutralization , epitope , virology , biology , antiserum , monoclonal antibody , peptide , human papillomavirus , antibody , neutralizing antibody , epidermodysplasia verruciformis , bovine papillomavirus , papillomaviridae , peptide vaccine , microbiology and biotechnology , cervical cancer , virus , immunology , cancer , gene , medicine , biochemistry , genetics , genome
We generated a monoclonal antibody, RG-1, that binds to highly conserved L2 residues 17 to 36 and neutralizes human papillomavirus 16 (HPV16) and HPV18. Passive immunotherapy with RG-1 was protective in mice. Antiserum to the HPV16 L2 peptide comprising residues 17 to 36 (peptide 17-36) neutralized pseudoviruses HPV5, HPV6, HPV16, HPV 18, HPV31, HPV 45, HPV 52, HPV 58, bovine papillomavirus 1, and HPV11 native virions. Depletion of HPV16 L2 peptide 17-36-reactive antibodies from cross-neutralizing rabbit and human L2-specific sera abolished cross-neutralization and drastically reduced neutralization of the cognate type. This cross-neutralization of diverse HPVs associated with cervical cancer, genital warts, andepidermodysplasia verruciformis suggests the possibility of a broadly protective, peptide-based vaccine.